Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Preparation and use of GH secretatogues disclosed by Merck & Co.

Sep. 3, 1998

Astra to reevaluate development strategy for Allelix's recombinant PTH

Sep. 3, 1998

Merck & Co. claims glucagon antagonists, cytokine inhibitors

Sep. 2, 1998

Banyu presents urea derivatives with NPY receptor-antagonist activity

Sep. 2, 1998

L-168721: potent, nonpeptide GH secretagogue

Sep. 2, 1998

P&U to market Glyset in U.S., Canada and several other countries

Sep. 2, 1998

Hemosol blood substitute to enter phase II clinical trials in U.S. for CABG

Sep. 2, 1998

Novartis continues to study DPP IV inhibitors; new lead reported at ACS meeting

Sep. 1, 1998

Novo Nordisk describes the first nonpeptide competitive glucagon antagonist

Sep. 1, 1998

Androsorb to enter second part of hormone replacement therapy trial

Sep. 1, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Medtronic bolsters pain portfolio in $650M SPR Therapeutics buy
BioWorld
Medtronic plc is strengthening its pain management portfolio with its $650 million move to buy SPR Therapeutics Inc. and bring the company’s peripheral nerve...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
BMS-Hengrui deal strikes panic in Washington
BioWorld
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...